Format

Send to

Choose Destination
Front Biosci (Schol Ed). 2020 Mar 1;12:161-172.

Beneficial effect of ivabradine against cardiovascular diseases.

Author information

1
Clinical Nutrition Unit, Department of Oral Medical and Biotechnological Sciences, Via dei Vestini 31, University of Chieti-Pescara, Italy, m.alessandra.gammone@gmail.com.
2
Cardiology Unit, San Camillo de Lellis, Hospital, Via Isonzo 1, Manfredonia, Foggia, Italy.
3
Cardiology Unit, Della Murgia Hospital, SS 96, KM 74.800, Altamura, Bari, Italy.
4
Clinical Nutrition Unit, Department of Oral Medical and Biotechnological Sciences, Via dei Vestini 31, University of Chieti-Pescara, Italy.

Abstract

Coronary artery disease (CAD) and heart failure (HF) are major worldwide threat to health and well-being. Important progress in the treatment of CAD and HF have contributed to a decline in mortality around the world. A considerable number of epidemiological studies reported a strong independent association between elevated heart rate and major cardiovascular risk factors including atherosclerosis, ventricular arrhythmias, and left ventricular dysfunction. Ivabradine (IVA) is a pure heart rate-lowering agent with well-documented anti-anginal and anti-ischemic properties comparable to well-established anti-anginal agents, such as beta-blockers and calcium channel blockers. The heart rate reduction with IVA is beneficial in patients with CAD, chronic stable angina pectoris, and chronic HF, with an acceptable tolerance and safety profile. The pharmacodynamic and pharmacokinetic properties of this drug make it an important agent in the management of patients with CAD and HF. The aim of this short review is to explore recent results with IVA, a new medication that lowers heart rate by selectively inhibiting the If current, and to describe others future potential applications.

PMID:
32114453

Supplemental Content

Full text links

Icon for Frontiers in Bioscience
Loading ...
Support Center